View on market: Volatility persists, eagerly searching for growth:

Asian stock markets slipped slightly in quiet trade as exchanges in China and Hong Kong remained shut for holidays. U.S. markets ended higher overnight, with all three main indexes posting small gains. Investors were relieved as worries about an immediate government shutdown in Washington eased, although political risks remain. Still, tensions grew after President Trump issued fresh warnings over the budget standoff with Democrats, keeping uncertainty alive. In bonds, U.S. Treasury yields were steady, while the dollar regained some strength after recent losses. Gold prices stayed close to record highs, showing that investors are still seeking safe assets. In India, focus has shifted to the Reserve Bank of India’s monetary policy decision. The repo rate to remain unchanged, but traders will watch closely for the central bank’s outlook on inflation, liquidity, and the rupee. The Nifty and Sensex closed marginally lower after another volatile session, marking the eighth straight day of losses. Automobile companies are set to announce their September sales data today, which could influence market sentiment further.

Economic Calendar:

• USD: S&P Global Manufacturing PMI on 01^st October 2025.
• IND: Auto Sales Numbers on 01^st October 2025.
• USD: Crude Oil Inventories on 01^st October 2025.
• IND: Monetary Policy on 01^st October 2025.

IPO Watch:

Brokerage Radar:

UBS ON BHEL:

Target Rs 340, BHEL secured Rs 15,000 crore order for Supercritical thermal power plants; approximately 17% of FY26 UBS estimates, Increases BHEL’s YTD order inflow to Rs 31,000 crore – 35% of FY26 UBS estimates, Order intake momentum remains positive, pickup in execution remains critical for re-rating.

CLSA ON GODREJ PROPERTIES:

Target Rs 2,850 Earlier Target Rs 2,770, Closing on a strong quarter, Estimate presales of Rs 8000-8500 crore in Q2; likely to beat guidance, Strong growth with improving cash flows/margin, Yet valuation at discount.

CITI ON SUN PHARMA:

Target Rs 2,180 Recommendation Sell, MFN Overhang is removed with Pfizer deal, Existing drug prices in the Medicare and commercial segments haven’t been touched, Removes a key overhang on Sun Pharma’s Ilumya, Sun Pharma now appear to been substantially abated, Sun Pharma preferred sector pick.

CLSA ON NAZARA TECH:

Target Rs 166, Real money gaming banned, Ban will hit Nazara’s PokerBaazi and e-sports de-subsidiarisation, Government will continue to promote esports and other online games, Nazars will take a hit in PokerBaazi, Ownership in fast-growing e-sports subsidiary Nodwin has fallen below 50%, Nazara stock valuation is expensive at 48x FY27 PE.

International Markets:

U.S & Europe:

*As per 01^th October.

Asian markets:

Stocks strong on Chart:

Commodities & Currency:

FIIs & DIIs:

News Updates:

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 214 

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

• all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
• No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

• EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
• EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

2. 2. 2. Compensation

• • EWL or its associates have not received any compensation from the subject company in the past twelve months;
  • EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;

• EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research

3. In respect of Public Appearances

• EWL or its associates have not received any compensation from the subject company in the past twelve months;
• The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL